HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine

Zong,Jinbao; Wang,Changyuan; Wang,Qingyong; Peng,Qinglin; Xu,Yufei; Xie,Xixiu; Xu,Xuemei

doi:10.3892/or.2013.2742

HSP70 and modified HPV 16 E7 fusion gene without the addition of a signal peptide gene sequence as a candidate therapeutic tumor vaccine

Authors:
- Jinbao Zong
- Changyuan Wang
- Qingyong Wang
- Qinglin Peng
- Yufei Xu
- Xixiu Xie
- Xuemei Xu
View Affiliations

Affiliations: Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking, Union Medical College, Beijing 100005, P.R. China
Published online on: September 20, 2013 https://doi.org/10.3892/or.2013.2742
Pages: 3020-3026

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Millions of women are currently infected with high-risk human papillomavirus (HPV), which is considered to be a major risk factor for cervical cancer. Thus, it is urgent to develop therapeutic vaccines to eliminate the established infections or HPV-related diseases. In the present study, using the mycobacterium tuberculosis heat shock protein 70 (MtHSP70) gene linked to the modified HPV 16 E7 (mE7) gene, we generated two potential therapeutic HPV DNA vaccines, mE7/MtHSP70 and SigmE7/MtHSP70, the latter was linked to the signal peptide gene sequence of human CD33 at the upstream of the fusion gene. We found that vaccination with the mE7/MtHSP70 DNA vaccine induced a stronger E7-specific CD8+ T cell response and resulted in a more significant therapeutic effect against E7-expressing tumor cells in mice. Our results demonstrated that HSP70 can play a more important role in mE7 and MtHSP70 fusion DNA vaccine without the help of a signal peptide. This may facilitate the use of HSP70 and serve as a significant reference for future study.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Clifford GM, Smith JS, Plummer M, et al: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 88:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
3	Quek SC, Lim BK, Domingo E, et al: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. Int J Gynecol Cancer. 23:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
4	Brown DR, Kjaer SK, Sigurdsson K, et al: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 199:926–935. 2009.PubMed/NCBI
5	Kemp TJ, Hildesheim A, Safaeian M, et al: HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 29:2011–2014. 2011. View Article : Google Scholar : PubMed/NCBI
6	Chen CH, Wang TL, Hung CF, et al: Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine. 18:2015–2022. 2000. View Article : Google Scholar : PubMed/NCBI
7	Brinkman JA, Xu X and Kast WM: The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Vaccine. 25:3437–3444. 2007. View Article : Google Scholar : PubMed/NCBI
8	Eiben GL, Velders MP, Schreiber H, et al: Establishment of an HLA-A0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A0201 transgenic mice. Cancer Res. 62:5792–5799. 2002.
9	Ohlschlager P, Pes M, Osen W, et al: An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine. 24:2880–2893. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gurunathan S, Klinman DM and Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 18:927–974. 2000. View Article : Google Scholar : PubMed/NCBI
11	Chen CH, Wang TL, Hung CF, et al: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60:1035–1042. 2000.PubMed/NCBI
12	Li Y, Subjeck J, Yang G, et al: Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine. 24:5360–5370. 2006. View Article : Google Scholar : PubMed/NCBI
13	Hauser H, Shen L, Gu QL, et al: Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Gene Ther. 11:924–932. 2004. View Article : Google Scholar : PubMed/NCBI
14	Milani V, Noessner E, Ghose S, et al: Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 18:563–575. 2002.PubMed/NCBI
15	Li Z, Menoret A and Srivastava P: Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol. 14:45–51. 2002. View Article : Google Scholar : PubMed/NCBI
16	Bendz H, Ruhland SC, Pandya MJ, et al: Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem. 282:31688–31702. 2007. View Article : Google Scholar
17	Udono H, Ichiyanagi T, Mizukami S, et al: Heat shock proteins in antigen trafficking - implications on antigen presentation to T cells. Int J Hyperthermia. 25:617–625. 2009. View Article : Google Scholar : PubMed/NCBI
18	Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 20:395–425. 2002. View Article : Google Scholar : PubMed/NCBI
19	Osterloh A and Breloer M: Heat shock proteins: linking danger and pathogen recognition. Med Microbiol Immunol. 197:1–8. 2008. View Article : Google Scholar : PubMed/NCBI
20	Binder RJ and Srivastava PK: Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8⁺ T cells. Nat Immunol. 6:593–599. 2005.PubMed/NCBI
21	Massa C, Guiducci C, Arioli I, et al: Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res. 64:1502–1508. 2004. View Article : Google Scholar : PubMed/NCBI
22	Murshid A, Gong J, Stevenson MA, et al: Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come. Expert Rev Vaccines. 10:1553–1568. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zong J, Peng Q, Wang Q, et al: Human HSP70 and modified HPV16 E7 fusion DNA vaccine induces enhanced specific CD8⁺ T cell responses and anti-tumor effects. Oncol Rep. 22:953–961. 2009.PubMed/NCBI
24	Trimble CL, Peng S, Kos F, et al: A phase I trial of a human papillomavirus DNA vaccine for HPV16⁺ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 15:361–367. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang QY, Xu YF, Fan DS, et al: Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8⁺T-lymphocyte induction and anti-tumour activity of DNA vaccine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 29:584–591. 2007.(In Chinese).
26	Feltkamp MC, Smits HL, Vierboom MP, et al: Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 23:2242–2249. 1993. View Article : Google Scholar
27	Tindle RW, Fernando GJ, Sterling JC, et al: A ‘public’ T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA. 88:5887–5891. 1991.
28	Hsu KF, Hung CF, Cheng WF, et al: Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 8:376–383. 2001. View Article : Google Scholar : PubMed/NCBI
29	Liu H, Wu BH, Rowse GJ, et al: Induction of CD4-independent E7-specific CD8⁺ memory response by heat shock fusion protein. Clin Vaccine Immunol. 14:1013–1023. 2007. View Article : Google Scholar : PubMed/NCBI
30	Huang Q, Richmond JF, Suzue K, et al: In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4⁺ T cell independent. J Exp Med. 191:403–408. 2000. View Article : Google Scholar : PubMed/NCBI
31	Delneste Y, Magistrelli G, Gauchat J, et al: Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 17:353–362. 2002. View Article : Google Scholar : PubMed/NCBI
32	Saito K, Dai Y and Ohtsuka K: Enhanced expression of heat shock proteins in gradually dying cells and their release from necrotically dead cells. Exp Cell Res. 310:229–236. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wang MH, Grossmann ME and Young CY: Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer. 90:926–931. 2004. View Article : Google Scholar : PubMed/NCBI
34	Mambula SS, Stevenson MA, Ogawa K, et al: Mechanisms for Hsp70 secretion: crossing membranes without a leader. Methods. 43:168–175. 2007. View Article : Google Scholar : PubMed/NCBI
35	Broquet AH, Thomas G, Masliah J, et al: Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release. J Biol Chem. 278:21601–21606. 2003. View Article : Google Scholar : PubMed/NCBI
36	Lancaster GI and Febbraio MA: Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem. 280:23349–23355. 2005. View Article : Google Scholar : PubMed/NCBI
37	Srivastava PK, Udono H, Blachere NE, et al: Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 39:93–98. 1994. View Article : Google Scholar : PubMed/NCBI
38	Srivastava PK and Udono H: Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 6:728–732. 1994. View Article : Google Scholar : PubMed/NCBI